CN114949034B - Application of perilla extract in preparing medicine for preventing and treating acute pneumonia - Google Patents
Application of perilla extract in preparing medicine for preventing and treating acute pneumonia Download PDFInfo
- Publication number
- CN114949034B CN114949034B CN202210511606.6A CN202210511606A CN114949034B CN 114949034 B CN114949034 B CN 114949034B CN 202210511606 A CN202210511606 A CN 202210511606A CN 114949034 B CN114949034 B CN 114949034B
- Authority
- CN
- China
- Prior art keywords
- perilla
- extract
- lung
- medicine
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000004347 Perilla Nutrition 0.000 title claims abstract description 66
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 31
- 244000124853 Perilla frutescens Species 0.000 title claims abstract description 23
- 210000004072 lung Anatomy 0.000 claims abstract description 50
- 210000001519 tissue Anatomy 0.000 claims abstract description 37
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 26
- 235000004348 Perilla frutescens Nutrition 0.000 claims abstract description 21
- 210000002381 plasma Anatomy 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 230000008595 infiltration Effects 0.000 claims abstract description 10
- 238000001764 infiltration Methods 0.000 claims abstract description 10
- 210000004969 inflammatory cell Anatomy 0.000 claims abstract description 10
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 239000003208 petroleum Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 238000002390 rotary evaporation Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002137 ultrasound extraction Methods 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 claims description 2
- ACBOFPQSBWBAQR-UHFFFAOYSA-N Cosmosiin Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(Oc3c2)c4cccc(O)c4)C(O)C(O)C1O ACBOFPQSBWBAQR-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 claims description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 2
- 235000008714 apigenin Nutrition 0.000 claims description 2
- 229940117893 apigenin Drugs 0.000 claims description 2
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009498 luteolin Nutrition 0.000 claims description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 2
- MGYBYJXAXUBTQF-TWJLCPPASA-N Luteolin rutinoside Chemical compound OC1[C@@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@H](O)C(O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 MGYBYJXAXUBTQF-TWJLCPPASA-N 0.000 claims 1
- SHPPXMGVUDNKLV-UHFFFAOYSA-N Veronicastroside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-UHFFFAOYSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- MGYBYJXAXUBTQF-FSFUDZCRSA-N luteolin 7-O-rutinoside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)c(O)c5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@H]1O MGYBYJXAXUBTQF-FSFUDZCRSA-N 0.000 claims 1
- MGYBYJXAXUBTQF-UHFFFAOYSA-N scolymoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 MGYBYJXAXUBTQF-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 32
- 206010061218 Inflammation Diseases 0.000 abstract description 29
- 230000004054 inflammatory process Effects 0.000 abstract description 29
- 206010069351 acute lung injury Diseases 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 8
- 230000001575 pathological effect Effects 0.000 abstract description 7
- 229930014626 natural product Natural products 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 17
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 229940100601 interleukin-6 Drugs 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 239000012530 fluid Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000003896 Myeloperoxidases Human genes 0.000 description 9
- 108090000235 Myeloperoxidases Proteins 0.000 description 9
- 102000003777 Interleukin-1 beta Human genes 0.000 description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000401 methanolic extract Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- XVULBTBTFGYVRC-HHUCQEJWSA-N sclareol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@](O)(C)C=C)[C@](C)(O)CC[C@H]21 XVULBTBTFGYVRC-HHUCQEJWSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000131458 Elsholtzia Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XVULBTBTFGYVRC-UHFFFAOYSA-N Episclareol Natural products CC1(C)CCCC2(C)C(CCC(O)(C)C=C)C(C)(O)CCC21 XVULBTBTFGYVRC-UHFFFAOYSA-N 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- LAEIZWJAQRGPDA-UHFFFAOYSA-N Manoyloxid Natural products CC1(C)CCCC2(C)C3CC=C(C)OC3(C)CCC21 LAEIZWJAQRGPDA-UHFFFAOYSA-N 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of an east perilla extract in preparing a medicine for preventing and treating acute pneumonia, wherein the medicine is a medicine for inhibiting lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation, inhibiting the expression of related inflammatory factors in the lung and inhibiting the expression of related inflammatory factors in blood plasma. The perilla frutescens extract can effectively inhibit the infiltration and protein exudation of bronchoalveolar inflammatory cells of lung tissues of mice with acute lung injury models under lower doses, inhibit the expression of related inflammatory factors in the lung and blood plasma of the mice with inflammatory models, and effectively improve pathological injury caused by inflammatory reaction of the lung of the mice; the raw materials of the invention are from natural products, which are convenient to collect and have high safety.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of an east perilla extract in preparing a medicine for preventing and treating acute pneumonia.
Background
Recent global new coronaviruses have had serious effects on countries around the world, and the new coronaviruses cause acute inflammatory responses characterized by deep airway and alveolar lesions of the lungs. If the lung inflammatory reaction is not controlled in time, the lung inflammatory reaction can be developed into various lung diseases, such as acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disease and the like, which are difficult to cure and have bad prognosis, and seriously affect the quality of life. An ideal model for researching the pulmonary inflammatory reaction is an animal acute lung injury model, although scientific researchers have conducted intensive studies on acute lung injury in laboratories and clinic, the mortality rate is still very high. And the western medicines for treating acute lung injury have larger side effects and are easy to generate drug resistance. In order to prevent or treat the acute pneumonia process, a safe and effective medicine for preventing or treating the acute pneumonia is sought from natural products.
Dongsu purple perillaElsholtiziabodinieriVannot) is a perennial herb of the genus elsholtzia of the family Labiatae, and is mainly divided intoIs distributed in Yunnan, guizhou and Gansu parts of China. The east perilla is a traditional plant for both food and medicine, is used as herbal tea for drinking in Yunnan, also called as small camellia, pine tea and the like in many minority nationalities, has the function of clearing heat and reducing fire, and is a natural health-care drink. In addition, the Dongsu-purple perilla is pungent and is used as a medicine by using whole herbs, and the Chinese herbal medicine assembly, yunnan Chinese herbal medicine and the like are recorded, so that the Chinese herbal medicine has the effects of relieving fever, easing pain, stopping vomiting, diminishing inflammation, resisting viruses and the like. It is reported that the east perilla is rich in triterpenes, aromatic oils, flavonoids, etc., and its extract has antioxidant, antifatigue and antiviral activities, and the east perilla extract is safe without mutagenic effects. However, at present, no patent literature report exists on the anti-inflammatory research of the perilla extract at home and abroad. The related research of the patent is funded by national natural science foundation (approval number: 32160106).
Disclosure of Invention
In order to solve the technical problems, the invention provides a novel application of the perilla extract in medicine, and the perilla extract is applied to the preparation of a novel medicament for preventing and/or treating acute pneumonia.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the first object of the invention is to provide an application of the perilla extract in preparing a medicament for preventing and treating acute pneumonia, wherein the medicament is a medicament for inhibiting lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation, inhibiting the expression of related inflammatory factors in the lung, inhibiting the expression of related inflammatory factors in blood plasma and improving pathological damage caused by lung inflammatory reaction.
Further, the perilla frutescens extract is prepared by the following method:
(1) Pulverizing Perilla frutescens into powder, decolorizing Perilla frutescens powder: adding petroleum ether, performing suction filtration, and performing rotary evaporation to recover petroleum ether to obtain Perilla frutescens residues;
(2) Airing the perilla residue in the step (1), adding 80% methanol solution, performing ultrasonic extraction, and performing suction filtration to obtain perilla residue;
(3) Adding 80% methanol solution into the east perilla filter residue in the step (2) for ultrasonic extraction for 2-3 times, and combining the extracting solutions; recovering methanol from the rotary evaporation extract until obtaining water phase; and (3) continuously concentrating the water phase by rotary evaporation to obtain a concentrated solution, pre-freezing the concentrated solution in a refrigerator at the temperature of minus 20 ℃, and freeze-drying the concentrated solution by a freeze dryer to obtain the perilla 80% methanol solution extract (freeze-dried powder).
Further, in the step (1), the mass-volume ratio of the east perilla powder to the petroleum ether is 1g to 10mL.
Further, the ultrasonic in the step (1) is ultrasonic for 30-35 min under the power of 60-70 w; the petroleum ether is recovered by rotary evaporation for 3 times.
Further, in the step (2) and the step (3), the mass-volume ratio of the east perilla residue to the methanol solution and the mass-volume ratio of the east perilla residue to the methanol solution are both 1g to 10mL.
Further, the ultrasonic extraction in the step (2) and the step (3) is carried out for 30-35 min under the power of 300-320 w.
In the invention, the concentration of the perilla extract in the medicine for preventing and treating acute pneumonia is preferably 200 mg/kg-600 mg/kg. The invention has no special requirements on the dosage form of the medicine, the auxiliary materials of the medicine and the preparation method of the medicine, and can be adopted by the people skilled in the art. The novel medicine for preventing and/or treating acute pneumonia uses the perilla extract as an active ingredient, is used for preparing the medicine for preventing and treating acute pneumonia, and can be added with one or more auxiliary materials acceptable in pharmaceutical preparations or compounded with other active ingredients to play a role in synergizing the acute pneumonia resistance.
The invention carries out a series of researches on the perilla extract for preventing and treating acute pneumonia. The perilla extract can obviously inhibit the infiltration of bronchoalveolar inflammatory cells and protein exudation of lung tissues; can obviously inhibit the expression of relevant inflammatory factors in the lung and plasma of an inflammation model mouse; can effectively improve pathological damage caused by pulmonary inflammatory reaction of mice; overall, the lung inflammation of the lipopolysaccharide-induced acute lung injury model mice is effectively improved, the lung function of the mice is improved, and the effect of preventing or treating acute pneumonia is almost equivalent to that of a blank control group. The perilla extract provided by the invention has remarkable effect on preventing and treating acute pneumonia, and the perilla has wide distribution, high safety, low cost and easily available raw materials; the perilla extract has good development and application prospect in preparing medicines for preventing and treating acute pneumonia.
In summary, compared with the prior art, the invention has the following advantages:
1. the invention discloses a new medical application for the perilla frutescens extract.
2. Experiments show that the perilla extract can effectively inhibit infiltration and protein exudation of bronchoalveolar inflammatory cells of lung tissues of mice with acute lung injury models, inhibit the expression of related inflammatory factors in the lung and blood plasma of the mice with inflammatory models, and effectively improve pathological injury caused by inflammatory reaction of the lung of the mice; the raw materials of the invention are from natural products, which are convenient to collect and have high safety.
3. The perilla extract of the invention has simple extraction process and low cost, and is suitable for industrial production and market popularization and application.
Drawings
FIG. 1 is a graph showing the results of liquid phase detection of the east Perilla frutescens prepared in example 1 of the present invention;
FIG. 2 is a bar graph showing the effect of the Perilla frutescens extract of the present invention on mouse bronchoalveolar lavage cells and proteins, wherein graph A shows bronchoalveolar lavage cell numbers; panel B shows bronchoalveolar lavage fluid protein amount; c is a blank control group; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM is positive group (dexamethasone);
FIG. 3 is a graph showing the expression level of inflammatory factors in the lung of a mouse according to the present invention, wherein graph A shows the expression level of IL-6 in the lung tissue of the mouse; panel B shows the amount of IL-1β expressed in lung tissue; panel C shows the amount of MPO expressed in lung tissue; c is a blank control group; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM is positive group (dexamethasone);
FIG. 4 shows the expression level of inflammatory factor in the plasma of mice of the present invention, wherein FIG. A shows the expression level of IL-6 in the plasma of mice; panel B shows the amount of IL-1β expressed in plasma of mice; panel C shows the amount of NO expressed in mouse plasma; c is a blank control group; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM is positive group (dexamethasone);
FIG. 5 is a HE staining pattern of lung tissue sections of mice according to the invention, wherein Control is a blank; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM was positive group (dexamethasone).
Detailed Description
The following description of at least one exemplary embodiment is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be made by one of ordinary skill in the art without undue burden on the person of ordinary skill in the art based on embodiments of the present invention, are within the scope of the present invention. Techniques, methods, and apparatus known to one of ordinary skill in the relevant art may not be discussed in detail, but should be considered part of the specification where appropriate. In addition, the technical features of the different embodiments of the present invention described below may be combined with each other as long as they do not collide with each other.
Examples
Preparation of the Dongsu extract of this example:
the whole plant of the east perilla is picked from the mountain of Yunnan mountain, and is dried naturally and then is crushed into powder to obtain the dry powder of the whole plant of the east perilla. Weighing 50g of whole plant dry powder of the east perilla, adding petroleum ether, carrying out ultrasonic treatment for 30min at the power of 60w, wherein the mass volume ratio of the dry powder of the east perilla to the petroleum ether is 1g to 10mL, carrying out suction filtration, carrying out rotary evaporation on the petroleum ether part for recycling, repeating for 3 times, and retaining the east perilla residues. Drying the decolorized east perilla residues, adding 80% methanol, performing ultrasonic treatment at 300w power for 30min, performing suction filtration, continuously adding 80% methanol into the obtained east perilla residues, performing ultrasonic treatment at 300w power for 30min, and keeping the extracting solution, wherein the mass volume ratio of the east perilla to the methanol is 1g to 10mL, and repeating the steps for 3 times; then, the mixture is subjected to rotary evaporation to extract until a rotary evaporation bottle only has water phase, methanol is recovered, the water phase is subjected to rotary evaporation concentration continuously, then, the mixture is pre-frozen in a refrigerator at the temperature of minus 20 ℃, and finally, the mixture is subjected to freeze-drying by a freeze dryer to obtain the perilla 80% methanol extract (freeze-dried powder).
The main chemical components of the 80% methanol extract of the perilla were qualitatively analyzed by UPLC-MS/MS technology, and the analysis results are shown in figure 1.
As can be seen from fig. 1: the 9 main chemical components of the Dongsu 80% methanol extract are quinic acid (1), chlorogenic acid (2), apigenin (3) and luteolin-7 respectivelyORutinoside (Luteolin-7)ORutinoside (4), formononetin (5), luteolin (6), cosmosiin (7), rosmarinic acid (8), (2R) eriodictyol 7-O-(6"-3,4-dihydroxycinnamoyl)-β-D-glucopyranoside（9）。
The invention provides application of the perilla frutescens extract obtained by the preparation method in preparation of medicines for treating acute pneumonia.
The invention also provides application of the perilla extract in preparing a medicament for preventing and treating acute pneumonia by inhibiting lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation.
The invention also provides application of the perilla extract in preparing a medicament for preventing and treating acute pneumonia by inhibiting the expression of related inflammatory factors in the lung.
The invention also provides application of the perilla extract in preparing a medicament for preventing and treating acute pneumonia by inhibiting the expression of related inflammatory factors in blood plasma.
The invention also provides application of the perilla extract in preparing a medicament for preventing and treating acute pneumonia by improving pathological damage caused by lung inflammatory reaction.
Examples
The present example is an evaluation of the activity of the perilla extract for preventing and treating acute pneumonia:
2.1 establishment and Experimental Process of acute pulmonary inflammation mouse model
Male C57BL/6J mice (about 20g in weight at 8 weeks of age) were used as subjects, and 15 mice were used in each group. Acute lung inflammatory reaction is induced by nasal perfusion LPS (0.5 mg/kg), a mouse acute lung injury model is constructed, and the model is built for 12 hours. The prevention and treatment effect of the perilla frutescens 80% methanol extract obtained in the stomach-filling example 1 on mice with acute lung injury induced by LPS was evaluated; mice were acclimatized for 7d in standard environment after purchase and were fed with standard feed. The specific experimental procedure and the grouping are as follows:
blank control group: the stomach is irrigated with an equal volume of purified water;
model group: LPS (0.5 mg/kg) was nasally infused with a pipette according to body weight, and molding was performed for 12 hours;
low dose group of eastern perilla: continuously irrigating for 7 days, and administering 200mg/kg of the 80% methanol extract of the east perilla, and molding for 24 hours by using LPS before dissection;
high dose group of eastern perilla: continuously irrigating for 7 days, and administering 600mg/kg of the 80% methanol extract of the east perilla, and molding for 24 hours by using LPS before dissection;
positive control group: 10mg/kg dexamethasone was given 1h lavage before molding, followed by nasal infusion of LPS (0.5 mg/kg) with a pipette according to body weight, molding for 24h;
2.2 detection of the effect of active ingredient on the cell number and protein content of bronchoalveolar lavage fluid of model mice:
2.2.1 taking groups of mice, performing tracheal intubation, lavaging bronchioalveoli with precooled PBS, taking lavage fluid, centrifuging at 4 ℃ for 5 minutes at 1500 revolutions, collecting supernatant, and detecting the total protein content by using a BCA kit; the remaining cells were resuspended in pre-chilled PBS, stained with Rayleigh-Giemsa complex stain (Wright-Giemsa) for 4 minutes, centrifuged to remove the dye, and immediately the macrophages and neutrophils were counted separately under a microscope using a hemocytometer.
2.2.2 experimental results:
effect of the east perilla extract on bronchoalveolar lavage fluid cell count and total protein content of model mice:
alveolar lavage fluid assay can be used to evaluate inflammatory response stages of interstitial lung disease, diagnosing lung disease. By analyzing the cell number and the total protein content of the bronchoalveolar lavage fluid, the method can be used for analyzing and detecting the disease states of certain respiratory diseases, and particularly can play a very important role in researching pathogenesis. When the lung is infected and inflammatory, alveolar inflammatory cell infiltration can occur, the cell number of alveolar lavage fluid can be obviously increased, the bronchoalveolar cell protein of lung tissue can exude, and the total protein content of the alveolar lavage fluid can be increased.
The effect of the Perilla frutescens extract on mice with acute lung injury model is evaluated by the cell number and total protein content of bronchoalveolar lavage fluid of each treated mouse, and the result is shown in figure 2, wherein figure A shows the cell number of bronchoalveolar lavage fluid, and figure B shows the protein content of bronchoalveolar lavage fluid. C is a blank control group; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM is positive group (dexamethasone); * Represents p <0.05; * Represents p <0.01.
2.3 detection of the effect of active ingredients on the expression of inflammatory factors and related proteins in lung tissue of model mice:
2.3.1 taking groups of mice, taking lung tissues by aseptic technique, flushing with aseptic precooled PBS, taking 100mg of lung tissues, adding 900 μl of aseptic precooled PBS for homogenizing at 4 ℃, centrifuging to obtain supernatant, and detecting the expression conditions of IL-6, IL-1 beta and MPO in the lung tissues of the groups of mice by using corresponding kits.
2.3.2 experimental results
Inflammatory factors refer to various cytokines involved in inflammatory reactions, and when the lung is stimulated from outside, immune responses are generated by lung cells, a large amount of inflammatory factors are secreted, and even stronger inflammatory reactions are initiated. Typical inflammatory factors include interleukin 6 (IL-6), interleukin 1 beta (IL-1 beta), myeloperoxidase (MPO), and the like. IL-6 is used as a multi-effect cytokine for pro-inflammation and regulating immunity, has the function of amplifying inflammation, and is involved in the occurrence and development processes of diseases and the inflammatory response and immune response of organisms. The damage of IL-6 to lung is mainly caused by inflammation caused by lung infection and oxidative stress to stimulate local macrophages and the like of lung tissues to activate, promote the secretion of IL-6, and IL-6 can activate the aggregation of neutrophils at the inflammation part, thereby releasing a large amount of enzymes and oxygen free radicals, and causing the increase of the permeability of pulmonary capillaries and the denaturation and necrosis of lung epithelial cells. IL-1β is a signal that initiates inflammation. MPO is a heme protein, which is enriched in neutrophils, synthesized in bone marrow and stored in azurin-phaga granules before they enter the circulation. MPO can kill microorganisms in phagocytes by catalyzing and oxidizing chloride ions to generate hypochlorous acid, destroy various target substances, and play roles in various aspects such as organism generation and regulation of inflammatory reaction.
The invention examines the influence of the Dongsu extract on the mice with acute lung injury by detecting the expression conditions of IL-6, IL-1 beta and MPO in the lung tissues of each group of mice by using the corresponding kit, and the effect is shown in figure 3. Wherein Panel A shows the amount of IL-6 expressed in lung tissue; panel B shows the amount of IL-1β expressed in lung tissue; panel C shows the MPO expression level in lung tissue. C is a blank control group; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM is positive group (dexamethasone); * Represents p <0.05.
The results in fig. 3 show that the eastern perilla extract significantly reduced IL-6 expression in lung tissue of mice with inflammation model (x, p < 0.05), IL-1 beta expression significantly reduced (x, p < 0.05), MPO expression significantly reduced (x, p < 0.05). The Perilla frutescens extract can obviously inhibit the expression of inflammatory factors related to the lung of an inflammation model mouse.
2.4 detection of the effect of active ingredient on inflammatory factors in model mouse plasma:
2.4.1 taking mice of each group, taking blood from the eyeballs of an anticoagulant tube, centrifuging for 5 minutes at 2500 rpm, taking supernatant plasma, and detecting the expression conditions of IL-6, IL-1 beta and NO in the plasma of the mice of each group by using a corresponding kit.
2.4.2 experimental results
NO has pro-inflammatory effects, and at the site of inflammation, NO acts on vascular smooth muscle cells, increasing its cGMP level, causing vasodilation and increased permeability, facilitating the arrival of inflammatory mediators and pain-causing substances at the site of action, and increasing the penetration of monocytes into the site of inflammation during the inflammatory response. In the pathogenesis of immune inflammation, elevated levels of NO in the body can affect the pathological process from a number of pathways.
The invention examines the influence of the sclareol extract on mice with acute lung injury by detecting the expression conditions of IL-6, IL-1 beta and NO in the plasma of each group of mice by using the corresponding kit, and the effect is shown in figure 4. Wherein Panel A shows the amount of IL-6 expressed in plasma; panel B shows the amount of IL-1. Beta. Expressed in plasma; panel C shows the amount of NO expressed in plasma. C is a blank control group; model is LPS induction Model group; EBEL is a low dose lavage group (200 mg/kg); EBEH is the high dose lavage group (600 mg/kg); DXM is positive group (dexamethasone); * Represents p <0.05, and p <0.01.
The results in fig. 4 show that the eastern perilla extract significantly reduced IL-6 expression in plasma of mice with inflammation model (x, p < 0.01), IL-1 β expression significantly reduced (x, p < 0.05), NO expression significantly reduced (x, p < 0.01). The Perilla frutescens extract can obviously inhibit the expression of related inflammatory factors in the plasma of mice with an inflammation model.
2.5 detection of the effect of active ingredient on lung tissue structure of model mice:
2.5.1 taking groups of mice, taking lung tissues by aseptic technique, washing with aseptic precooled PBS, fixing to prepare paraffin sections, and observing the change condition of tissue structure under a microscope after HE staining.
The preparation method of paraffin sections comprises the following steps:
(1) Drawing materials: fresh lung tissue was fixed with 10% formalin solution for more than 24 h. Taking out the lung tissue from the fixing solution, trimming the tissue of the target part in a fume hood by using a surgical knife, and placing the trimmed tissue and a corresponding label in a dehydration box;
(2) Dewatering and immersing wax: and (5) placing the dehydration box into a dehydrator to sequentially carry out gradient alcohol dehydration. 75% alcohol 4h,85% alcohol 2h,90% alcohol 2h,95% alcohol 1h, absolute alcohol I30 min, absolute alcohol II 30min, alcohol benzene 5-10min, xylene I5-10 min, xylene II 5-10min, paraffin I1 h melted at 65 ℃, paraffin II 1h melted at 65 ℃, paraffin III 1h melted at 65 ℃;
(3) Embedding: embedding the wax-soaked tissue in an embedding machine. Firstly, putting melted wax into an embedding frame, taking out tissues from a dehydration box before the wax is solidified, putting the tissues into the embedding frame according to the requirement of an embedding surface, and attaching corresponding labels. Cooling at-20deg.C, solidifying, removing the wax block from the embedding frame, and trimming;
(4) Slicing: placing the trimmed wax block into a paraffin slicer for slicing, wherein the thickness of the wax block is 4 mu m; the slices float on warm water at 40 ℃ of a slice spreading machine to flatten the tissues, the glass slide drags the tissues out, the slices are baked in a baking oven at 60 ℃, and the slices are taken out for preservation at normal temperature after being baked with water and wax.
The HE staining method is as follows:
(1) Paraffin sections dewaxed to water: sequentially placing the slices into xylene I20 min-xylene II 20 min-absolute ethanol I5 min-absolute ethanol II 5min-75% ethanol 5min, and washing with tap water;
(2) Hematoxylin staining: slicing, dyeing with hematoxylin dye solution for 3-5min, washing with tap water, differentiating with differentiation solution, washing with tap water, and washing with running water;
(3) Eosin staining: the slices are dehydrated in gradient alcohol of 85% and 95% for 5min respectively, and then are dyed in eosin dye solution for 5min.
(4) And (3) removing the water sealing piece: sequentially slicing, adding absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5 min-absolute ethyl alcohol III 5 min-xylene I5 min-xylene II 5min, and sealing with neutral resin;
(5) Microscopic examination, image acquisition and analysis.
2.5.2 experimental results
The experiment adopts HE staining to observe the lung tissue structure of the mice, and the result is shown in figure 5.
From the results of fig. 5, it can be seen that the perilla extract significantly reduces inflammatory exudates between bronchoalveoli, significantly reduces inflammatory cell infiltration of tissues, and maintains the integrity of bronchoalveolar epithelial cells. The results show that the perilla extract can obviously improve pathological damage caused by pulmonary inflammatory reaction of mice.
The preparation method of the perilla frutescens extract comprises the following steps: ultrasound is carried out for 35min under 70w power by adding petroleum ether or 33min under 65w power by adding petroleum ether, ultrasonic extraction is carried out for 35min or 32min under 320w power by 80% methanol, and the rest materials are the same as those in the examples, thus preparing the kedong perilla extract for preventing and treating acute pneumonia.
In conclusion, the perilla frutescens extract can remarkably inhibit the infiltration of bronchoalveolar inflammatory cells and protein exudation of lung tissues; can obviously inhibit the expression of relevant inflammatory factors in the lung and plasma of an inflammation model mouse; can effectively improve pathological damage caused by pulmonary inflammatory reaction of mice. The perilla extract provided by the invention has remarkable effect on preventing and treating acute pneumonia, and the raw materials are from natural products, so that the perilla extract is high in safety and low in cost, and is suitable for industrial production and market popularization and application.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Although embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives, and variations may be made in the above embodiments by those skilled in the art without departing from the spirit and principles of the invention.
Claims (5)
1. The application of the perilla extract in preparing a medicine for preventing and treating acute pneumonia is characterized in that the medicine is a medicine for inhibiting lung tissue bronchoalveolar inflammatory cell infiltration and protein exudation, inhibiting the expression of related inflammatory factors in the lung and inhibiting the expression of related inflammatory factors in blood plasma;
the perilla extract is prepared by the following steps:
(1) Pulverizing Perilla frutescens into powder, decolorizing Perilla frutescens powder, adding petroleum ether, performing ultrasonic treatment, and vacuum filtering to recover petroleum ether by rotary evaporation to obtain Perilla frutescens residue;
(2) Airing the perilla residue in the step (1), adding 80% methanol solution, performing ultrasonic extraction, and performing suction filtration to obtain perilla residue;
(3) Adding 80% methanol solution into the east perilla filter residue in the step (2) for ultrasonic extraction for 2-3 times, and combining the extracting solutions; recovering methanol from the rotary evaporation extract until obtaining water phase; continuously concentrating the water phase by rotary evaporation to obtain a concentrated solution, pre-freezing the concentrated solution in a refrigerator at the temperature of-20 ℃, and freeze-drying the concentrated solution by a freeze dryer to obtain an extract of the perilla 80% methanol solution;
the said methanol solution extract of Perilla Frutescens L.80% comprises quinic acid, chlorogenic acid, apigenin, luteolin-7-O-rutinoside, formononetin, luteolin, cosmosiin, rosmarinic acid, R-eriodictyol-7-O- (6' -3, 4-dihydroxycinnamoyl) -BETA-D-glucoside.
2. The use of the extract of eastern perilla according to claim 1 for preparing a medicine for preventing and treating acute pneumonia, wherein in the step (1), the mass-volume ratio of the eastern perilla powder to the petroleum ether is 1 g/10 ml.
3. The use of the perilla frutescens extract according to claim 1 in preparing a medicament for preventing and treating acute pneumonia, wherein the ultrasound in the step (1) is ultrasound for 30-35 min under the power of 60-70 w; the petroleum ether is recovered by rotary evaporation for 3 times.
4. The application of the perilla extract according to claim 1 in preparing a medicine for preventing and treating acute pneumonia, wherein in the step (2) and the step (3), the mass-volume ratio of perilla residue to methanol solution and the mass-volume ratio of perilla residue to methanol solution are 1 g/10 ml.
5. The application of the perilla frutescens extract according to claim 1 in preparing medicines for preventing and treating acute pneumonia, wherein the ultrasonic extraction in the step (2) and the step (3) is carried out for 30-35 min under the power of 300-320 w.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210511606.6A CN114949034B (en) | 2022-05-12 | 2022-05-12 | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210511606.6A CN114949034B (en) | 2022-05-12 | 2022-05-12 | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114949034A CN114949034A (en) | 2022-08-30 |
| CN114949034B true CN114949034B (en) | 2023-11-07 |
Family
ID=82981289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210511606.6A Active CN114949034B (en) | 2022-05-12 | 2022-05-12 | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114949034B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116392518B (en) * | 2023-04-19 | 2024-03-15 | 昆明理工大学 | Application of perilla and extract thereof in preparing medicine for treating chronic pressure brain lesions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156889A (en) * | 2004-04-10 | 2008-04-09 | 云南省药物研究所 | Application of east purple common perilla extractive |
| CN113398222A (en) * | 2020-03-17 | 2021-09-17 | 云南中医药大学 | National medicine composition for exorcising evil spirits and preventing epidemic |
-
2022
- 2022-05-12 CN CN202210511606.6A patent/CN114949034B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156889A (en) * | 2004-04-10 | 2008-04-09 | 云南省药物研究所 | Application of east purple common perilla extractive |
| CN113398222A (en) * | 2020-03-17 | 2021-09-17 | 云南中医药大学 | National medicine composition for exorcising evil spirits and preventing epidemic |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114949034A (en) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091203B (en) | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof | |
| CN111870568B (en) | Anti-allergy itching-relieving plant composition and preparation method and application thereof | |
| CN114949034B (en) | Application of perilla extract in preparing medicine for preventing and treating acute pneumonia | |
| CN107382474A (en) | A kind of production method of Traditional Chinese medicine fertilizer | |
| CN109601795A (en) | Using penthorum chinense pursh as composition alcohol-decomposing beverage of primary raw material and preparation method thereof | |
| CN104208294B (en) | It is a kind of to be used to treat Chinese medicine composition of piglet yellow-white dysentery and preparation method thereof | |
| CN105617316A (en) | Antibacterial disinfectant for clinical laboratory and preparation method | |
| CN105168385A (en) | Antibacterial and itching-relieving medicine composition and preparing method thereof | |
| KR20180104516A (en) | Method for producing medicine of skin diseases | |
| CN112674239A (en) | Chinese herbal medicine compound feed additive for fish and preparation method and application thereof | |
| CN112675278A (en) | Composition for moistening lung to arrest cough and inhibiting lung inflammatory reaction and preparation method and application thereof | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| WO2006007758A1 (en) | Traditional chinese medicine composition for treating acute and chronic nasosinusitis and preparation thereof | |
| CN108619165A (en) | Application of the Polysaccharide from Scutellaria Baicalensis in preparing veterinary drug | |
| CN114728030B (en) | Composition for preventing, alleviating or treating respiratory diseases | |
| CN108542926A (en) | The preparation method and pharmaceutical composition of a kind of purslane extract and its application | |
| CN115025137A (en) | External traditional Chinese medicine extract for promoting wound healing and extraction method and application thereof | |
| CN112920927A (en) | Traditional Chinese medicine compound vinegar composition and preparation method thereof | |
| KR20200040427A (en) | Method for producing medicine of skin diseases | |
| CN115844933B (en) | Application of clindamycin total flavone in preparing heart failure resisting medicine | |
| CN109381607A (en) | A kind of pharmaceutical composition and its preparation process treated blood disease and merge bacterium infection | |
| CN107929372A (en) | Treat Chinese medicine composition of onychomycosis and its preparation method and application | |
| KR101249559B1 (en) | Preparation method of concentrated powder included scutellaria radix and alnus japonica | |
| CN117100819A (en) | Application of red rice seed coat active extract in preparation of medicine for preventing and treating acute alcoholic liver disease | |
| CN107510836A (en) | A kind of bitter gourd polypeptide pharmaceutical composition for treating diabetic ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |